IC Disease

Stella Pharmaceuticals in Canada has released some promising new information on a recent clinical trial of a drug called Uracyst®.  The controlled clinical study was done through Watson Pharmaceuticals, a United States licensee of Stella Pharmaceuticals. 

This study was a multi-centre, randomized, double blind, evaluation of the efficacy and safety of Uracyst versus placebo in patients with Interstitial Cystitis.  This is exciting news for Interstitial Cystitis, as another new drug to help the condition may be available.  Currently Elmiron is the only FDA approved drug for IC Disease.

The positive results shown from this clinical trial and pilot study will help Watson more forward with the next steps that will eventually lead to FDA approval.

To read more, click here.

Trackback URI | Comments RSS